Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Michael S. Rooney"'
Autor:
Asaf Poran, Dewi Harjanto, Matthew Malloy, Christina M. Arieta, Daniel A. Rothenberg, Divya Lenkala, Marit M. van Buuren, Terri A. Addona, Michael S. Rooney, Lakshmi Srinivasan, Richard B. Gaynor
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Abstract Background The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/9f61d50420b745d5900a6a515483100a
Autor:
Moshe Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen, Michael S. Rooney, Michal Barzily-Rokni, Jean-Pierre Eliane, Stacey L. Bjorgaard, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Dennie T. Frederick, Mehlika Hazar-Rethinam, Brandon A. Nadres, Emily E. Van Seventer, Sachet A. Shukla, Keren Yizhak, John P. Ray, Daniel Rosebrock, Dimitri Livitz, Viktor Adalsteinsson, Gad Getz, Lyn M. Duncan, Bo Li, Ryan B. Corcoran, Donald P. Lawrence, Anat Stemmer-Rachamimov, Genevieve M. Boland, Dan A. Landau, Keith T. Flaherty, Ryan J. Sullivan, Nir Hacohen
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
Externí odkaz:
https://doaj.org/article/4b7fd694a84645dbafce545e168de8d2
Publikováno v:
Cell Reports, Vol 9, Iss 1, Pp 180-192 (2014)
Summary: Deficiencies in DNA-degrading nucleases lead to accumulation of self DNA and induction of autoimmunity in mice and in monogenic and polygenic human diseases. However, the sources of DNA and the mechanisms that trigger immunity remain unclear
Externí odkaz:
https://doaj.org/article/66c5e70d8f4242128f45bf816a862b3c
Autor:
Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh, David R. Spigel, Edward B. Garon, Meghan E. Bushway, Asaf Poran, Joong Hyuk Sheen, Victoria Kohler, Ekaterina Esaulova, John Srouji, Suchitra Ramesh, Rohit Vyasamneni, Binisha Karki, Tracey E. Sciuto, Himanshu Sethi, Jesse Z. Dong, Melissa A. Moles, Kelledy Manson, Michael S. Rooney, Zakaria S. Khondker, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan
Publikováno v:
Cancer cell. 40(9)
Neoantigens arising from mutations in tumor DNA provide targets for immune-based therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a personalized neoantigen-vaccine NEO-PV-01 in combination with pemetrexed, carbo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::935d29553f74594992b9744ac0684da4
https://pubmed.ncbi.nlm.nih.gov/36027917
https://pubmed.ncbi.nlm.nih.gov/36027917
Autor:
Christina M. Arieta, Richard B. Gaynor, Marit M. van Buuren, Daniel A. Rothenberg, Dewi Harjanto, Michael S. Rooney, Divya Lenkala, Lakshmi Srinivasan, Asaf Poran, Terri A. Addona, Matthew Malloy
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Genome Medicine
Genome Medicine
BackgroundThe ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.MethodsWe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2581207271d87340ff429c2da2bbaab
https://doi.org/10.1186/s13073-020-00767-w
https://doi.org/10.1186/s13073-020-00767-w
Autor:
Meghan E. Bushway, Kristen N. Balogh, Lakshmi Srinivasan, Zakaria S. Khondker, Patrick A. Ott, Rana H. Besada, Richard B. Gaynor, Julian Scherer, Jasmina Prabhakara, Siwen Hu-Lieskovan, Michael S. Rooney, Reid G. Williams, Amy Wanamaker, Asaf Poran
Publikováno v:
Cell Reports Medicine
Summary T cells use highly diverse receptors (TCRs) to identify tumor cells presenting neoantigens arising from genetic mutations and establish anti-tumor activity. Immunotherapy harnessing neoantigen-specific T cells to target tumors has emerged as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::454be1df2b0d61360ad4496862fe793c
https://pubmed.ncbi.nlm.nih.gov/33294862
https://pubmed.ncbi.nlm.nih.gov/33294862
Autor:
Lakshmi Srinivasan, Matthew Malloy, Dewi Harjanto, Michael S. Rooney, Asaf Poran, Richard B. Gaynor
BackgroundThe ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Consistent with observations for SARS-CoV, a closely related coronavirus responsible for the 2003 SARS outbre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6419157cf318267d65ed1ea450664a
https://doi.org/10.1101/2020.04.06.027805
https://doi.org/10.1101/2020.04.06.027805
Autor:
Lakshmi Srinivasan, Yvonne Ware, Kelledy Manson, Asaf Poran, Benjamin Trapp, Joel Greshock, Mark M. Awad, Dominik Barthelme, Dewi Harjanto, Victoria Kohler, Ying S. Ting, Richard B. Gaynor, Yuting Huang, Matthew D. Hellmann, Samantha J. Turnbull, Siwen Hu-Lieskovan, Ed Fritsch, Meghan E. Bushway, Jessica J. Lin, Lisa D. Cleary, Bartosz Chmielowski, Zhengping Huang, Michael S. Rooney, Terence W. Friedlander, Rana H. Besada, Patrick A. Ott, Zakaria S. Khondker, Mark DeMario, Kristen N. Balogh, Aung Naing, Melissa A. Moles, Riley R. Curran, Kim Margolin, Nina Bhardwaj, Tracey E. Sciuto, Jesse Z. Dong, Ramaswamy Govindan, Julian Scherer, Amy Wanamaker
Publikováno v:
Cell. 183(2)
Summary Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515738446c00429f62713aedbb493a4c
https://pubmed.ncbi.nlm.nih.gov/34781699
https://pubmed.ncbi.nlm.nih.gov/34781699
Autor:
Jared L. Dietze, Daniel A. Rothenberg, Terri A. Addona, Antoine Boudot, Jessica Kohler, Jennifer G. Abelin, Vikram R. Juneja, Paul J. Turcott, Brandon P. Conn, Marit M. van Buuren, Scott P. Goulding, Christopher D. McGann, Richard B. Gaynor, John R. Srouji, Kendra C. Foley, Jae Won Choi, Michael S. Rooney, Divya Lenkala
Publikováno v:
Cell Reports Methods. 1:100084
Summary Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c80a975d5d541b12214cf886b5d9702
https://doi.org/10.1016/j.crmeth.2021.100084
https://doi.org/10.1016/j.crmeth.2021.100084
Autor:
Guang Lan Zhang, Wandi Zhang, Siranush Sarkizova, Catherine J. Wu, Derin B. Keskin, William J. Lane, Nir Hacohen, Michael S. Rooney, Jennifer G. Abelin, Karl R. Clauser, Jonathan Stevens, John Sidney, Steven A. Carr, Thomas Eisenhaure, Christina R. Hartigan
Publikováno v:
Immunity. 46:315-326
Identification of human leukocyte antigen (HLA)-bound peptides by liquid chromatography-tandem mass spectrometry (LC-MS/MS) is poised to provide a deep understanding of rules underlying antigen presentation. However, a key obstacle is the ambiguity t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c863c06a03b3f5066bed5df7da95b4c1
https://doi.org/10.1016/j.immuni.2017.02.007
https://doi.org/10.1016/j.immuni.2017.02.007